Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 versus NEPHRAMINE 5 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 versus NEPHRAMINE 5 4.
AMINOSYN II 3.5% vs NEPHRAMINE 5.4%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids serve as substrates for protein synthesis, providing essential and non-essential nitrogen sources for anabolism in patients unable to tolerate oral or enteral nutrition.
Provides essential amino acids for protein synthesis in patients with renal impairment, reducing nitrogen waste accumulation.
Intravenous infusion of 250-500 mL/day (8.75-17.5 g amino acids) as a component of parenteral nutrition; rate up to 125 mL/hour; titrate based on metabolic response.
500 mL to 1000 mL intravenously over 8-24 hours, containing 5.4% amino acids, typically as a component of total parenteral nutrition; dose adjusted based on metabolic needs and protein requirements (usual 0.8-1.5 g/kg/day amino acids).
None Documented
None Documented
Terminal elimination half-life of individual amino acids ranges from 10 to 30 minutes for most, with glutamine and arginine slightly longer (30–45 min). No defined half-life for the mixture; clinically, steady-state achieved in 2–3 hours with continuous infusion.
1-2 hours (endogenous amino acid pool turnover); clinical context: continuous infusion required to maintain plasma levels.
Renal: 95% of infused amino acids are reabsorbed; excess amino acids are deaminated and urea is excreted renally. Fecal/Biliary: negligible (<1%).
Renal: >90% as amino acids and metabolites. Biliary/fecal: negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution